Cargando…
Combining selinexor with alisertib to target the p53 pathway in neuroblastoma
Neuroblastoma accounts for 15% of cancer-related deaths in children, highlighting an unmet need for novel therapies. Selinexor is a small molecule inhibitor of XPO1. XPO1 shuffles cargo proteins with a nuclear export sequence from the nucleus to the cytosol, many of which are essential for cancer gr...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Neoplasia Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866064/ https://www.ncbi.nlm.nih.gov/pubmed/35217309 http://dx.doi.org/10.1016/j.neo.2022.100776 |